GSK (GLAXF) Stock Based Compensation: $0 Mil (TTM As of Mar. 2026)


GLAXF GSK PLC GLAXF
75 GF Score
Price $25.33
GF Value $21.09
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is GSK Stock Based Compensation?

GSK GLAXF 75 Stock Based Compensation is $0 Mil as of Mar. 2026. GuruFocus rates GLAXF with a GF Score™ of 75/100 and a GF Value™ of $21.09 (Modestly Overvalued). The stock has 1 warning sign investors should review.

GSK's Stock Based Compensation for the three months ended in Mar. 2026 was $0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

GSK Stock Based Compensation Related Terms

GSK Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for GSK's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GSK Stock Based Compensation Chart

GSK Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 456.12 421.44 388.61 434.89 500.67

GSK Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GLAXF
75GF Score
GSK PLC GLAXF
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GSK Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

What does a Stock Based Compensation of $0 Mil mean?
GSK (GLAXF) has a Stock Based Compensation of $0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for GSK and its competitors.
Is GSK's Stock Based Compensation too high?
GSK's current Stock Based Compensation is $0 Mil. Overall, GSK has a GF Score™ of 75/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does GSK's Stock Based Compensation compare to LLY and JNJ?
GSK's Stock Based Compensation of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Drug Manufacturers company?
A good Stock Based Compensation depends on the Drug Manufacturers industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for GSK and its competitors. GSK's current Stock Based Compensation is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GSK stock overvalued right now?
Based on GuruFocus' analysis, GSK (GLAXF) is currently considered Modestly Overvalued. The stock's GF Value™ is $21.09, compared to a current price of $25.33 — trading 20.1% above its estimated fair value. The current Stock Based Compensation is $0 Mil. GSK's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For GSK (GLAXF), the current Stock Based Compensation is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GSK (GLAXF) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of $25.33 is trading 20.1% above its estimated GF Value™ of $21.09. GuruFocus considers GSK to be Modestly Overvalued.

Key valuation signals for GLAXF:

  • Stock Based Compensation: $0 Mil
  • GF Value™: $21.09 vs. price of $25.33 (20.1% above fair value)
  • GF Score™: 75/100 with 1 warning sign

No single metric tells the full story. See the GLAXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
75GF Score

Get the complete analysis for GLAXF

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.33
Price
$21.09
GF Value